Manila mayor Lito Atienza has stated that he will arrest anyone who attempts to ship the abortion pill RU-486 into the city, dubbing the pill as a “do-it-yourself murder kit”. His statement was in response to an announcement made by the Philippine secretary of health authorizing RU-486 for victims of rape and incest. The pill, also known as mifepristone, has recently been approved for use in the United States by the Food and Drug Administration.
Mifepristone (RU486) is a medical breakthrough in women’s health overall and a safe, effective method of terminating pregnancy in 49 days or less. The pill is administered orally, is non-invasive, requires no anesthesia, and bears less risk of infection. Many women prefer mifepristone because the procedure is more private and allows them greater psychological control in ending a pregnancy. In addition, medical studies have shown mifepristone shows promise as a possible treatment for uterine fibroid tumors, ovarian cancer, endometriosis, meningioma (brain tumors), some types of breast cancer and other serious diseases and conditions that mostly affect women. The Feminist Majority Foundation has for the past twelve years campaigned to make mifepristone available to women in the United States, both as an abortion pill and also alternative treatment, or compassionate use, to serious illnesses affecting women’s heath.
Media Resources: ZENIT News Agency 9 October 2000, Feminist Majority Foundation, U.S. Department of Health and Human Services
1/27/2016 Taiwan Elects First Woman President - In a landslide victory, the leader of Taiwan's Democratic Progressive Party (DPP) Tsai Ing-wen won the country's presidential election, becoming the first woman in Taiwan's history to hold the position.
Emphasizing her party's commitment to maintaining Taiwan's independence from China, Tsai won over young voters eager to usher in a political changing of the guard following some 70 years of dominance by the pro-Chinese unification party, the Kuomintang (KMT), chaired by presidential opponent Eric Chu. . . .